Наукові видання (НН МІ)
Permanent URI for this collectionhttps://devessuir.sumdu.edu.ua/handle/123456789/132
Browse
Search Results
Item Arg16Gly polymorphism in the β2-adrenoceptor gene in patients with bronchial asthma(ALUNA Publishing, 2021) Качковська, Владислава Володимирівна; Kachkovska, Vladyslava Volodymyrivna; Ковчун, Анна Володимирівна; Kovchun, Anna Volodymyrivna; Моісеєнко, Ірина Олегівна; Moiseyenko, Iryna Olehivna; Дудченко, Ірина Олександрівна; Dudchenko, Iryna Oleksandrivna; Приступа, Людмила Никодимівна; Prystupa, Liudmyla NykodymivnaThe aim: The objective of the study was to analyze the frequency of Arg16Gly polymorphism in the β2-adrenoceptor (β2-АR) gene in patients with bronchial asthma (BA) and to assess the association of the polymorphism with BA risk. Materials and methods: We examined 553 BA patients and 95 apparently healthy individuals. Arg16Gly polymorphism in the β2-АR gene (rs1042713) was determined using polymerase chain reaction-restriction fragment length polymorphism analysis. Statistical analysis of obtained results was performed using SPSS–17 program. Results: It was established that distribution of Arg/Arg, Arg/Gly, and Gly/Gly genotypes for Arg16Gly polymorphism in the β2-АR gene was 44.2%, 40.0%, 15.8% in the control group vs. 31.3%; 45.7% and 23.0 among BA patients, respectively (χ2 = 6.59; р = 0.037). No significant difference was observed with regards to the distribution of genotypes for Arg16Gly polymorphism in the β2-АR gene in men and women controls (χ2 = 4.05; р = 0.13) and BA patients (χ2 = 4.34; р = 0.11). BA risk was 1.74 times higher in the minor allele carriers (Arg/Gly + Gly/Gly genotypes) for Arg16Gly polymorphism in the β2-АR gene. Conclusions: Analysis of Arg16Gly polymorphic variants in the β2-AR gene showed a statistically significant difference in the distribution of Arg/Arg, Arg/Gly, and Gly/Gly genotypes in patients with BA and apparently healthy individuals due to the higher frequency of Arg/Arg genotype in controls and higher frequency of Gly/Gly genotype in patients with asthma. No difference with regard to gender was found in the distribution of genotypes.Item The chronic kidney disease risk analysis in patients with arterial hypertension and coexistent hyperuricemia(ALUNA Publishing, 2021) Чернацька, Ольга Миколаївна; Chernatska, Olha Mykolaivna; Приступа, Людмила Никодимівна; Prystupa, Liudmyla Nykodymivna; Фадєєва, Ганна Анатоліївна; Fadieieva, Hanna Anatoliivna; Ляшенко, Аліна Володимирівна; Liashenko, Alina Volodymyrivna; Погорєлова, Оксана Сергіївна; Pohorielova, Oksana Serhiivna; Ополонська, Наталія Олексіївна; Opolonska, Nataliia OleksiivnaThe aim: Is the analysis of chronic kidney disease risk in patients with arterial hypertension and coexistent hyperuricemia. Materials and methods: We observed 40 patients with arterial hypertension and coexistent hyperuricemia (I group), 35 – with arterial hypertension (II group) and 30 practically healthy people (control). The duration of hypertension was 4,3 ± 2,31 years and 4,0 ± 2,11 years (p = 0,9247) for I and II group respectively, of hyperuricemia – 4,1 ± 0,35 years for I group. Categories of albuminuria (А1, А2, А3) and glomerular filtration rate (G1, G2, G3A, G3B, G4, G5) were determined in all observed patients. Clinical, anthropometric, biochemical, immunoassay, statistical (SPSS 21, Graph Pad) methods were used. Results: The categories of albuminuria and glomerular filtration rate in patients from the I group demonstrated that A1G1 was confirmed in 3 persons, A1G2 – 5, A2G1 – 7, A2G2 – 20, A1G3A – 1, A1G3B – 1, A2G3A – 2, A2G3B – 1. Among patients from the II group category A1G1 was defined in 7, A1G2 – 2, A2G1 – 16, A2G2 – 10 persons. The percent of low chronic kidney disease risk was on 5,7 % higher in hypertensive persons comparable with comorbid persons. High and very high risk was confirmed in 10 % persons from I group and nobody from the ІІ group. Conclusions: Chronic kidney disease risk is increased in patients with arterial hypertension and coexistent hyperuricemia. This indicates an association between elevated uric acid levels and chronic kidney disease progression.